TruTag Technologies to Present Live Webcast on Evaluating Product Security Risk and On Dose Authentication during Drug Development
Webcast hosted by Pharmaceutical Technology will address risk assessment of drug products during the drug development process
EMERYVILLE, CALIFORNIA ─ February 8, 2018 — TruTag Technologies, a leading security and technology solution provider, announced today that TruTag’s President, Kent Mansfield and Ron Guido, an industry consultant and former Vice President of Global Brand Protection for Johnson & Johnson, will be presenting a free webinar entitled, “Assessing Product Integrity Risk Profiles and Engineering On-Dose Authentication During Drug Development Process” on Thursday, February 15 at 1:00pm EST.
During this presentation, Mansfield and Guido will discuss how to properly assess security risk profiles for new drugs in development and determine the best practice to introduce, test and budget for the inclusion of potential ‘on-dose’ solutions to protect these products after commercial launch. Moreover, details will be provided about a silicon dioxide, encoded micro-particle verification solution and methods to integrate this solution during manufacturing. Other subject matter to be discussed will include the timing for assessments of potential solutions, regulatory considerations, budgeting, and cost parameters.
In this webcast, attendees will:
- Learn the analysis techniques for assessing and evaluating product integrity risks for new drug products in development;
- Keep up-to-date with the latest advancements in on-dose verification technologies to mitigate unauthorized diversion and falsification of solid dose product;
- Discover the product intelligence features that can be generated using integrated ‘on board’ verification technologies like TruTag’s SiO2 physical markers.
This webcast is useful for brand security teams, executives, research personnel, regulatory and administrative personnel, senior level scientists, marketing managers, and brand and product managers.
“If you want to learn the analysis techniques for evaluating product integrity risk for new drug products including potential for falsification, diversion, product liability, consumer safety, and dilution of revenue, you won’t want to miss this webinar,” said Kent Mansfield, President of TruTag Technologies. “We’ll go over the conditional decision process to help with scoring these security risks and if an “on-product” verification solution may be something to consider and test during development.”
To register for the free webcast, please click here.
About TruTag Technologies, Inc.
TruTag Technologies, Inc. is a leading security and technology solution provider serving businesses and governments around the world. TruTag has the most advanced precision-fabricated, cGMP nano-porous silica manufacturing operation in the world for a variety of applications and security solutions, including product identity for food, medicine, secure labels and documents. The company’s highly-specialized nano-porous silica particles extend to precision drug delivery systems for the biopharmaceutical industry. TruTag’s nano-fabrication technology platform is complemented by its advanced hyperspectral imaging solutions, which can be applied to a broad array of market applications from medical diagnostics to machine vision.
TruTag Technologies has been recognized by the SPIE Prism Awards, the Edison Awards, Fast Company, R&D 100, and was selected a Technology Pioneer by the World Economic Forum as one of the most influential technology companies in the world. Learn more at www.TruTags.com.
©2018 All rights reserved. TRUTAG and TRUTAGS are registered trademarks of TruTag Technologies, Inc.